Nov. 14 at 11:04 AM
( 2)
$LCTX And now the big one:
The Janus Henderson acquisition adds a major positive signal that the market seems to be ignoring.
Large, respected institutions don’t increase exposure to micro-cap biotech unless they see long-term value and asymmetric upside.
This kind of buying strengthens the shareholder base, reduces weak hands, and increases the probability of future institutional inflows.
When you combine all of this with the typical hedge-fund pressure and short-side tactics (liquidity games, sentiment algos, forced selling), it’s no surprise that the price action looks disconnected from fundamentals.
At this point, it feels like
$LCTX needs a full-time IR person just to constantly feed bots and algos the correct, simplified narrative — otherwise the market keeps reacting to noise instead of reality.
